Do analysts prefer BPTH or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BPTH or PRPH more profitable?

Bio-Path has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. ProPhase Labs' return on equity of -482.05% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% ProPhase Labs -825.01% -482.05% -88.90%

Do analysts prefer PRPH or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts prefer ATXI or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ASLN or PRPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate PRPH or NMTR?

Given 9 Meters Biopharma's higher possible upside, analysts plainly believe 9 Meters Biopharma is more favorable than ProPhase Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 9 Meters Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

ProPhase Labs (PRPH) Competitors

$0.02 0.00 (-4.52%)

As of 12:22 PM Eastern

Compare

PRPH vs. BPTH, ITRM, ATXI, ASLN, and NMTR

Should you buy ProPhase Labs stock or one of its competitors? ProPhase Labs's main competitors and comparable companies include Bio-Path (BPTH), Iterum Therapeutics (ITRM), Avenue Therapeutics (ATXI), ASLAN Pharmaceuticals (ASLN), and 9 Meters Biopharma (NMTR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ProPhase Labs compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Bio-Path has higher earnings, but lower revenue than ProPhase Labs. Bio-Path is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
ProPhase Labs	$5.06M	0.08	-$53.36M	-$2.25	N/A

Bio-Path has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. ProPhase Labs' return on equity of -482.05% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
ProPhase Labs	-825.01%	-482.05%	-88.90%

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bio-Path has a beta of -0.51, meaning that its stock price is 151% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
ProPhase Labs	Neutral

Summary

ProPhase Labs beats Bio-Path on 8 of the 11 factors compared between the two stocks.

How does ProPhase Labs compare to Iterum Therapeutics?

ProPhase Labs (NASDAQ:PRPH) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ProPhase Labs has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market.

In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Iterum Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Iterum Therapeutics has lower revenue, but higher earnings than ProPhase Labs. Iterum Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.08	-$53.36M	-$2.25	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

Iterum Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Iterum Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Iterum Therapeutics	N/A	N/A	-65.54%

Summary

Iterum Therapeutics beats ProPhase Labs on 8 of the 12 factors compared between the two stocks.

How does ProPhase Labs compare to Avenue Therapeutics?

Avenue Therapeutics (NASDAQ:ATXI) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
ProPhase Labs	Neutral

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Avenue Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Avenue Therapeutics' return on equity of -471.57% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
ProPhase Labs	-825.01%	-482.05%	-88.90%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Avenue Therapeutics has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Avenue Therapeutics has higher earnings, but lower revenue than ProPhase Labs. Avenue Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A
ProPhase Labs	$5.06M	0.08	-$53.36M	-$2.25	N/A

Summary

Avenue Therapeutics beats ProPhase Labs on 6 of the 11 factors compared between the two stocks.

How does ProPhase Labs compare to ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and ProPhase Labs (NASDAQ:PRPH) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
ProPhase Labs	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ASLAN Pharmaceuticals has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. ProPhase Labs' return on equity of -482.05% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
ProPhase Labs	-825.01%	-482.05%	-88.90%

ASLAN Pharmaceuticals has higher revenue and earnings than ProPhase Labs. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
ProPhase Labs	$5.06M	0.08	-$53.36M	-$2.25	N/A

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 9.6% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Summary

ASLAN Pharmaceuticals and ProPhase Labs tied by winning 6 of the 12 factors compared between the two stocks.

How does ProPhase Labs compare to 9 Meters Biopharma?

ProPhase Labs (NASDAQ:PRPH) and 9 Meters Biopharma (NASDAQ:NMTR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

9 Meters Biopharma has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. ProPhase Labs' return on equity of -482.05% beat 9 Meters Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
9 Meters Biopharma	N/A	-584.97%	-159.45%

9 Meters Biopharma has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.08	-$53.36M	-$2.25	N/A
9 Meters Biopharma	N/A	N/A	-$43.77M	-$3.46	N/A

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 22.3% of 9 Meters Biopharma shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by company insiders. Comparatively, 2.4% of 9 Meters Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Given 9 Meters Biopharma's higher possible upside, analysts plainly believe 9 Meters Biopharma is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
9 Meters Biopharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ProPhase Labs has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, 9 Meters Biopharma has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled 9 Meters Biopharma'saverage media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
9 Meters Biopharma	Neutral

Summary

ProPhase Labs and 9 Meters Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRPH vs. The Competition

Export

Metric	ProPhase Labs	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$382K	$12.01B	$7.12B	$12.85B
Dividend Yield	N/A	2.62%	2.54%	11.27%
P/E Ratio	-0.01	785.16	272.89	25.51
Price / Sales	0.08	957.31	686.41	123.12
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	0.01	10.48	11.06	6.34
Net Income	-$53.36M	$2.83B	$3.47B	$349.45M
7 Day Performance	N/A	0.23%	1.28%	-0.10%
1 Month Performance	N/A	5.33%	8.29%	4.36%
1 Year Performance	N/A	6.01%	24.29%	14.91%

ProPhase Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRPH ProPhase Labs	N/A	$0.02 -4.5%	N/A	-99.3%	$382K	$5.06M	N/A	130	Gap Up
BPTH Bio-Path	N/A	$0.03 -3.3%	N/A	-75.9%	$1.64M	N/A	N/A	10	Gap Down High Trading Volume
ITRM Iterum Therapeutics	0.0393 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10
ATXI Avenue Therapeutics	N/A	$0.41 +59.2%	N/A	-20.7%	$1.35M	N/A	0.02	4	Gap Up High Trading Volume
ASLN ASLAN Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$1.23M	$12M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRPH) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProPhase Labs (PRPH) Competitors

PRPH vs. BPTH, ITRM, ATXI, ASLN, and NMTR

How does ProPhase Labs compare to Bio-Path?

Summary

How does ProPhase Labs compare to Iterum Therapeutics?

Summary

How does ProPhase Labs compare to Avenue Therapeutics?

Summary

How does ProPhase Labs compare to ASLAN Pharmaceuticals?

Summary

How does ProPhase Labs compare to 9 Meters Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProPhase Labs (PRPH) Competitors

PRPH vs. BPTH, ITRM, ATXI, ASLN, and NMTR

How does ProPhase Labs compare to Bio-Path?

Which has higher earnings and valuation, BPTH or PRPH?

Is BPTH or PRPH more profitable?

Do institutionals and insiders believe in BPTH or PRPH?

Do analysts prefer BPTH or PRPH?

Which has more volatility and risk, BPTH or PRPH?

Does the media refer more to BPTH or PRPH?

Summary

How does ProPhase Labs compare to Iterum Therapeutics?

Do institutionals & insiders have more ownership in PRPH or ITRM?

Which has more risk & volatility, PRPH or ITRM?

Does the media prefer PRPH or ITRM?

Do analysts prefer PRPH or ITRM?

Which has preferable valuation and earnings, PRPH or ITRM?

Is PRPH or ITRM more profitable?

Summary

How does ProPhase Labs compare to Avenue Therapeutics?

Does the media favor ATXI or PRPH?

Do insiders & institutionals have more ownership in ATXI or PRPH?

Is ATXI or PRPH more profitable?

Do analysts prefer ATXI or PRPH?

Which has more volatility & risk, ATXI or PRPH?

Which has higher valuation & earnings, ATXI or PRPH?

Summary

How does ProPhase Labs compare to ASLAN Pharmaceuticals?

Does the media refer more to ASLN or PRPH?

Do analysts recommend ASLN or PRPH?

Is ASLN or PRPH more profitable?

Which has stronger earnings & valuation, ASLN or PRPH?

Do institutionals and insiders hold more shares of ASLN or PRPH?

Which has more volatility & risk, ASLN or PRPH?

Summary

How does ProPhase Labs compare to 9 Meters Biopharma?

Is PRPH or NMTR more profitable?

Which has higher earnings & valuation, PRPH or NMTR?

Do institutionals & insiders hold more shares of PRPH or NMTR?

Do analysts rate PRPH or NMTR?

Which has more risk & volatility, PRPH or NMTR?

Does the media prefer PRPH or NMTR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools